• 21

    June

    Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improve ... Read more

    21

    June

    New phase 3a liraglutide 3 mg data showed positive impact on cardiovascular risk ... Read more

    14

    June

    New phase 3 study shows efficacy and safety of Victoza® for the treatment of typ ... Read more

    14

    June

    New one-year data of IDegLira shows glucose-lowering effect was maintained for p ... Read more

  • 21

    July

    Share repurchase programme ... Read more

    14

    July

    Share repurchase programme ... Read more

    07

    July

    Share repurchase programme ... Read more

    01

    July

    Share repurchase programme ... Read more

  • 19

    June

    Exane 17th European CEO Seminar, Paris

    26

    June

    J.P. Morgan European Healthcare Conference, London

    7

    August

    Financial statement for the first six months of 2014

    30

    October

    Financial statement for the first nine months of 2014

Stock quotes

255.00 +2.95

Advanced view

Key events


Q2 2014 financial report release 

On 7 August 2014 Novo Nordisk will release results for the first six months of 2014. The release will be followed by a conference call with executive management.

 

The conference call will be transmitted via webcast from 13:00-14:00 CET and a presentation will be available from the download centre.

 

Link to the conference call webcast will be available here.

Latest uploads

Conference calls
Conference call on haemophilia
Shareholder magazine
Share Q1 2014
Interim reports
First three months of 2014 results
IR presentations
ADA investor presentation
General Meetings
Annual General Meeting

Related links

Printed reports and other publications
Order  

Dividend and stock split information
See

Investor package for the first quarter of 2014
Earnings conference call
Roadshow presentation
Company Announcement
Downloadable financial data